MicroRNA-3129 (miR-3129)

MicroRNA-3129 (miR-3129) is a small non-coding RNA molecule belonging to the microRNA family, involved in the post-transcriptional regulation of gene expression. It is recognized by its mature sequence, processed through nucleolytic cleavage of precursor transcripts typical of the miRNA biogenesis pathway[4][1]. In gastric cancer, miR-3129 has been shown to function as an oncogene by promoting cell proliferation and cell cycle progression—specifically, it is upregulated in tumor tissues and acts by increasing the expression of cyclin E, CDK2, and phosphorylated Rb protein (pRb), facilitating G1/S cell cycle transition[2]. Its regulatory effect includes downregulation of CDK inhibitors (p16, p21) and upregulation of drivers of cell proliferation; pRb appears to mediate the proliferative effects of miR-3129[2]. While its molecular and pathological roles are most strongly characterized in gastric cancer, previous reports have linked miR-3129 to colorectal and breast cancer risk, implying a broader contribution to cancer biology[2]. No clinically approved drugs currently target miR-3129, though it may serve as a promising molecular therapy candidate or a biomarker for proliferation in certain cancers[2].

Other names

hsa-mir-3129mir-3129MIR3129

Not applicable (miRNAs modulate gene expression post-transcriptionally; specific drug mechanisms not established for miR-3129)